SCHEMBL26115162

SCHEMBL26115162

CC(C)(C)OC(=O)N1CCN(C(=O)c2ccc(Br)c3cc[nH]c23)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.46
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ PARP1 P09874 1/20 0.41
▸ JAK1 P23458 3/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ TYK2 P29597 1/20 0.40
▸ JAK3 P52333 1/20 0.40
▸ LMNA P02545 2/20 0.40
▸ CRBN Q96SW2 1/20 0.39
▸ CHRM2 P08172 1/20 0.38
▸ CHRM4 P08173 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ CHRM3 P20309 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ KRAS P01116 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25337613 0.85 BACE1 (0.44) MEN1KMT2AJAK1JAK2TYK2
SCHEMBL26119201 0.81 MAPK14 (0.40) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL5704915 0.80 DRD2 (0.50) MEN1KMT2AJAK1JAK2TYK2
SCHEMBL19297086 0.78 BRD4 (0.53) JAK1JAK2TYK2JAK3
SCHEMBL31210541 0.77 GOT1 (0.47) POLBMEN1KMT2AJAK1JAK2
SCHEMBL31210747 0.75 GOT1 (0.46) MEN1KMT2AJAK1JAK2TYK2
SCHEMBL223688 0.75 POLB (0.61) POLBMEN1KMT2APARP1LMNA
SCHEMBL20140820 0.74 LMNA (0.43) MEN1KMT2ALMNAKCNH2ALDH1A1
SCHEMBL13872064 0.72 POLB (0.68) POLBMEN1KMT2APARP1LMNA
SCHEMBL1516226 0.72 KMT2A (0.53) POLBMEN1KMT2ALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250205344-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-06-26 — — US disclosed
EP-4499628-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-02-05 — — EP disclosed
WO-2023180388-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250205344-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS CRBN, AR, GNRHR POLB 4378/4885MEN1 1265/4885KMT2A 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback